Recursion Pharmaceuticals (RXRX) Stock Statistics & Valuation Metrics

Recursion Pharmaceuticals has a market cap or net worth of $2.30B. The enterprise value is $1.78B.

Recursion Pharmaceuticals has 395,072,080 shares outstanding. The number of shares has decreased by -2.65% in one year.

Recursion Pharmaceuticals’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -37.23%.

The current PE Ratio of Recursion Pharmaceuticals is -4.00. Recursion Pharmaceuticals’s PEG ratio is -0.57.

In the last 12 months, Recursion Pharmaceuticals had revenue of 58.84M and earned -463.66M in profits. Earnings per share was -1.69.

In the last 12 months, operating cash flow was -359.17M and capital expenditures -14.04M, giving a free cash flow of -373.22M billion.

Recursion Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Recursion Pharmaceuticals upcoming earnings date is May 7, 2025, TBA Not Confirmed.

Recursion Pharmaceuticals as a current ratio of 3.81, with Debt / Equity ratio of 10.48%

In the past 12 months, Recursion Pharmaceuticals has paid -1.13M in taxes.

Recursion Pharmaceuticals EV to EBITDA ratio is -3.21, with an EV/FCF ratio of -3.67.

Recursion Pharmaceuticals has $594.35M in cash and marketable securities with $108.49M in debt, giving a net cash position of -$485.86M billion.

Gross margin is 10.66%, with operating margin of -814.09%, and net profit margin of -788.02%.

The average price target for Recursion Pharmaceuticals is $8.75, which is 11.43% higher than the current price. The consensus rating is Hold